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L e t t e r s t o t h e E d i t o r
Task- Versus Amphetamine-Induced Displacement
of High-Affinity D2/3 Receptor Ligands
TO THE EDITOR: We have read with great interest a recent
article by Ceccarini et al. (1). In their study, the authors evaluated
the sensitivity of a single PET scan with the high-affinity do-
pamine D2/3 receptor ligand 18F-fallypride to reward-induced
dopamine release. Ceccarini et al. concluded that striatal and
extrastriatal dopamine release can be measured using a single
18F-fallypride PET scan, if the timing and peak magnitude of the
dopamine release are appropriate. Furthermore, their human
PET and simulation experiments suggested that performance
of a reward learning task during the scan, that is, during the in-
terval in which radioligand binding occurs, induced displacement
of the ligand in extrastriatal regions of the reward circuit, notably
in the orbitofrontal cortex. These findings are generally in line
with existing, albeit limited, literature on this theme; the report
by Ceccarini et al. is of particular interest, being one of the
first examining the dependence of competition on timing and mag-
nitude of the endogenous dopamine release in the cerebral cortex.
The question of whether dopamine release can be captured in
vivo is the theme of the well-established competition paradigm,
notably on pharmacologic challenge with amphetamine. Indeed,
amphetamine is a powerful releaser of dopamine, with a dose-
dependent action that seems ideally suited to examine the
sensitivity of radioligand binding to changes in endogenous
dopamine concentration. Whereas amphetamine challenge evoked
a reduction in 18F-fallypride binding in striatum of anesthetized
mice (2) and likewise in awake humans (3), the evidence is sub-
stantially less compelling for extrastriatal binding sites of 18F-
fallypride (4). Similarly, amphetamine challenge evoked only
5%–10% declines in the local cortical binding of the alternate
high-affinity dopamine D2/3 ligand 11C-FLB 457 (5), whereas the
same research group had earlier reported that a working memory
task evoked widespread 10%–15% reductions in cortical binding of
that ligand (6). In view of the well-known behavioral and physio-
logic effects of amphetamine, one might expect that amphetamine
challenge should provoke a greater dopamine release than occurs
during a cognitive task. Thus, it remains to be established how
performing a cognitive task might evoke a greater or more pro-
longed decline in the availability of cortical dopamine D2/3
receptors than can be evoked by amphetamine. This same res-
ervation seems relevant to the observations of reward/learning-
dependent 18F-fallypride binding changes now reported by
Ceccarini et al. Given that benzamide binding in living brain
is influenced by changes in cerebral blood flow (7) and dependent on
global perfusion (8), and in consideration that the blood oxygen
level–dependent signal in orbitofrontal cortex is altered during re-
ward processing (9), have the authors considered that their
observations with 18F-fallypride PET might be vulnerable to
confounds arising from altered cerebral perfusion? We suggest
that this consideration may call for systematic preclinical in-
vestigation of the effects of focally altered cerebral perfusion,
as may occur during performance of cognitive tasks, on cortical
18F-fallypride binding.
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REPLY: We read with interest the comments by Yakushev et al.
regarding our article (1) examining the dependence of competition
on the timing and magnitude of endogenous striatal and extrastria-
tal dopamine release using a single 18F-fallypride PET recording
and the linearized simplified reference region model (LSSRM) (2).
As they point out correctly, marked changes in regional cerebral
blood flow (rCBF) can be a potential confounding factor in detec-
ting neurotransmitter release (3). It could thus be hypothesized
that the results reported in the in vivo reward task study as part
of the article (1) may simply be due to a change in 18F-fallypride
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delivery or tissue efflux and not to competing dopamine release
induced by a reward task.
We argue that in this single-injection protocol with the combination
of the in vivo kinetics of 18F-fallypride and the LSSRM approach, it is
unlikely that rCBF-related changes would add major perturbations in
ligand displacement, also under task paradigm conditions, as was also
already stipulated by other simulation studies (2,4).
Although the LSSRM has several advantages by virtue of its
requiring only single-day scanning and a single synthesis and ad-
ministration of the radiochemical, and consequently avoiding ses-
sion effects, practical implementation of the model implies that
possible time-dependent alterations in rCBF are not fully accounted
for. Briefly, as described in Equation 2 in the supplemental mate-
rial of our article (1), the LSSRM can account for changes in
perfusion via the b-parameter. Implementation of the full model
is best suited for estimation of 4 parameters at a time. Attempts to
estimate more than 4 parameters would result in a large covariance
between the time-dependent parameters (a, b, and g), translating
into unreliable estimates. Therefore, parameters were customarily
estimated by fixing a 5 b 5 0 and estimating the other 4 param-
eters (R, k2, k2a, and g). This has indeed the potential of biasing
the g-estimate (i.e., 18F-fallypride displacement).
Previous simulation studies have investigated the effects of
transient increased ligand displacement and increased rCBF—
considering possibilities such as proportional increase in transport
(K1) and clearance rate (k2) so that the distribution volume remained
constant—and separate increases in K1 and k2 (4). In the case of
simultaneous increases, the changes in the PET binding curves are
negligible. Increasing K1 results in an increased tracer uptake with
negative g-estimates. On the other hand, an increase of 10% in k2
results in significant positive g-parameters. Therefore, the only
possible confounding circumstance causing a positive measure-
ment of g due to blood flow alterations is an exclusive increase
in k2. If the permeability/surface product is assumed constant, a
10% increase in K1 corresponds to a blood flow increase of ap-
proximately 30% for a typical flow rate of 0.5 mL/(gmin) (5).
Assuming that the nondisplaceable binding is unaffected by the
activation condition, a 10% increase in k2 would also correspond
to a 30% blood flow increase. This magnitude of blood flow increase,
however, is not within the expected range during performance of
a reward task. Activation perfusion studies with 15O-H2O and
functional MRI have shown that the increase in orbitofrontal rCBF
during performance of a monetary reward task is on the order of
few percentage points (6–8). Nevertheless, simulations of the ac-
tivation state have demonstrated that the LSSRM fits the data well
even when rCBF-related effects were on the order of 20% (2). This
rCBF-related issue was also addressed by Slifstein et al. (5), sug-
gesting that artifactual rCBF-induced changes in measured radio-
ligand binding are minor for 18F-fallypride.
In addition, the recent findings of Cumming et al. (9) gave pre-
liminary evidence that individual differences in global perfusion
(using an image-derived surrogate of mean global cerebral blood
flow) may bias the estimation of 18F-fallypride nondisplaceable
binding potential in the striatum but not in low-binding regions
(i.e., thalamus and the inferior temporal lobe). Therefore, although
rCBF may be a factor influencing the estimation of 18F-fallypride
nondisplaceable binding potential in regions with high receptor
concentrations (i.e., striatal regions), this influence should be less
important in low-binding regions (i.e., extrastriatal regions), where
changes were observed in the monetary reward task study.
We therefore are confident that our observations with 18F-fallypride
and LSSRM are not artifacts of non–receptor-related effects such
as altered cerebral perfusion and that the increased radioligand
washout k2a in response to reward-induced stimulation actually
reflects reduced nondisplaceable binding potential detecting the
presence of endogenous dopamine neurotransmission.
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